Steven Treon

75PUBLICATIONS
239CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (75)

|Jul 08, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

|Apr 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

|Mar 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Jorge J Castillo, Andrew R Branagan, Alberto Guijosa

|Mar 07, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications.

Alberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs

|Feb 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu

|Feb 03, 2026
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Alberto Guijosa, Nicholas Tsakmaklis, Margaret Kobs

Pageof 13

Frequent Collaborators

58 joint publications

Jorge J Castillo

38 joint publications

Zachary R Hunter

20 joint publications

Shayna Sarosiek

20 joint publications

Andrew R Branagan